Neville Rodie & Shaw Inc. Has $8.74 Million Stake in Celgene Corporation (CELG)
Neville Rodie & Shaw Inc. grew its stake in shares of Celgene Corporation (NASDAQ:CELG) by 4.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 67,318 shares of the biopharmaceutical company’s stock after purchasing an additional 3,015 shares during the period. Neville Rodie & Shaw Inc.’s holdings in Celgene Corporation were worth $8,743,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Celgene Corporation during the first quarter valued at $118,000. Oakworth Capital Inc. lifted its holdings in shares of Celgene Corporation by 60.9% during the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock valued at $136,000 after purchasing an additional 412 shares during the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its holdings in shares of Celgene Corporation by 47.5% during the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 380 shares during the last quarter. Nicolet Bankshares Inc. purchased a new stake in shares of Celgene Corporation during the first quarter valued at $187,000. Finally, Independent Portfolio Consultants Inc. lifted its holdings in shares of Celgene Corporation by 209.4% during the first quarter. Independent Portfolio Consultants Inc. now owns 1,541 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 1,043 shares during the last quarter. 79.43% of the stock is owned by institutional investors and hedge funds.
Shares of Celgene Corporation (CELG) traded up 1.02% during mid-day trading on Friday, reaching $142.04. The company had a trading volume of 5,983,997 shares. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $142.69. The company has a market capitalization of $111.12 billion, a price-to-earnings ratio of 43.99 and a beta of 1.89. The firm’s 50-day moving average is $134.97 and its 200 day moving average is $127.46.
Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping analysts’ consensus estimates of $1.61 by $0.21. The firm had revenue of $3.27 billion for the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business’s revenue was up 18.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.44 earnings per share. On average, equities research analysts predict that Celgene Corporation will post $7.33 earnings per share for the current year.
In other Celgene Corporation news, insider Robert J. Hugin sold 175,970 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the transaction, the insider now owns 1,033,909 shares of the company’s stock, valued at $138,688,553.26. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Michael D. Casey sold 9,250 shares of the business’s stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $125.59, for a total value of $1,161,707.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 267,476 shares of company stock worth $35,812,841. Company insiders own 0.95% of the company’s stock.
Several equities research analysts have recently commented on the company. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $175.00 target price (up from $148.00) on shares of Celgene Corporation in a report on Monday, July 31st. Cantor Fitzgerald set a $160.00 price target on Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, July 27th. BMO Capital Markets reissued an “outperform” rating and set a $160.00 price target (up from $152.00) on shares of Celgene Corporation in a research report on Friday, July 28th. Canaccord Genuity set a $156.00 price target on Celgene Corporation and gave the company a “buy” rating in a research report on Tuesday, June 6th. Finally, BidaskClub raised Celgene Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. One analyst has rated the stock with a sell rating, seven have issued a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $149.34.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.